Thursday, September 26, 2019 4:26:50 PM
DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefamulin) and CONTEPO™ (fosfomycin) clinical development programs will be presented at IDWeek 2019, to be held October 2-9 in Washington, D.C.
Nabriva, along with its collaborators, will present a total of 14 posters, including 11 for lefamulin and three for fosfomycin. Lefamulin data being presented has been generated from the company’s community-acquired bacterial pneumonia (CABP) clinical trial and in vitro surveillance programs. In addition, the company will present clinical data for CONTEPO from the Phase 2/3 pivotal study for the treatment of complicated urinary tract infections (cUTIs) as well as epidemiologic and prevalence data of U.S. hospitalized patients with difficult-to-treat, drug-....
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM